文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

术前单次与分次立体定向放疗:299个切除转移瘤的单机构分析

Preoperative Single-Fraction Versus Fractionated Stereotactic Radiation Therapy: A Single-Institutional Analysis of 299 Resected Metastases.
PubMed 文献 · Adv Radiat Oncol · 2026-06-17

结果显示SRS与FSRT的复合终点发生率分别为11%和12%,两者均安全有效,但需前瞻性匹配队列验证疗效与毒性差异。

要点

  • 术前SRS与FSRT治疗可切除脑转移瘤均安全有效。
  • SRS与FSRT的复合终点发生率分别为11%和12%。
  • 需前瞻性匹配队列比较两种术前放疗模式的疗效与毒性。

核心结论

  • 术前SRS和FSRT均是治疗可切除脑转移瘤安全有效的选择。
  • 有必要开展前瞻性匹配队列比较术前SRS与FSRT的疗效和毒性差异。

研究设计与样本

  • 单机构回顾性分析,纳入接受手术切除且术前对至少一个脑转移瘤行放疗的患者。

主要发现

  • SRS组4个(6.3%)和FSRT组6个(2.6%)转移瘤发生局部失败。
  • SRS组4个(6.2%)和FSRT组21个(9.1%)转移瘤发生2级及以上放射性坏死。
  • SRS组3个(4.7%)和FSRT组11个(4.7%)转移瘤诊断软脑膜疾病。
  • SRS组3个(4.6%)和FSRT组8个(3.4%)患者发生经典型脑膜疾病;SRS组0个(0%)和FSRT组4个(1.7%)患者发生结节型脑膜疾病。
  • SRS组11%和FSRT组12%的转移瘤发生复合终点。

关键数值与推荐

  • 主要终点为复合终点,定义为局部失败、结节型脑膜疾病和/或2级及以上(症状性)放射性坏死。

临床怎么用

  • 对于可切除脑转移瘤,术前SRS和FSRT均可作为安全有效的治疗选项。
  • 临床选择术前放疗方案时需权衡局部失败、放射性坏死和脑膜疾病风险,并期待前瞻性匹配研究提供更高级别证据。

局限性

  • 非随机对照,可能存在选择偏倚,需前瞻性匹配队列验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The treatment standard for patients with large or symptomatic brain metastases and limited intracranial disease is surgical resection followed by postoperative stereotactic radiosurgery (SRS). Preoperative SRS may lead to a reduced incidence of radiation necrosis (RN), local failure (LF), and nodular meningeal disease (nMD). Fractionated treatments may reduce the incidence of LF and nMD. We hypothesize that preoperative fractionated stereotactic radiation therapy will reduce the incidence rate of RN, LD, and nMD compared to patients receiving preoperative SRS. METHODS AND MATERIALS: Patients who had surgical resection and preoperative radiation to at least one brain metastasis at a single institution were retrospectively analyzed. Outcomes were evaluated on a per-lesion basis. The primary outcome was a composite endpoint defined by (1) LF; (2) nMD; and/or (3) grade 2 or higher (symptomatic) RN. RESULTS: 299 resected brain metastases from 260 patients were eligible for analysis. Two hundred thirty-five metastases received fractionated stereotactic radiation therapy (FSRT) and 64 received SRS. Thirty-eight patients had multiple metastases resected preoperatively. Overall, 4 (6.3%) SRS and 6 (2.6%) FSRT metastases experienced LF. Four (6.2%) SRS and 21 (9.1%) FSRT metastases experienced grade 2 or higher RN. Three (4.7%) SRS and 11 (4.7%) FSRT metastases were diagnosed with leptomeningeal disease. Additionally, 3 (4.6%) and 0 (0%) of SRS, and 8 (3.4%) and 4 (1.7%) of FSRT patients experienced classical or nodular meningeal disease, respectively. Eleven percent and 12% of SRS and FSRT metastases experienced the composite endpoint. CONCLUSIONS: In our study, preoperative SRS and FSRT both appear to be safe and effective options to treat resectable brain metastases. It is important to prospectively compare preoperative SRS and FSRT in matched cohorts to assess any differences in treatment efficacy and toxicity.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Perlow HK, Luu S, Reddy S, et al. Preoperative Single-Fraction Versus Fractionated Stereotactic Radiation Therapy: A Single-Institutional Analysis of 299 Resected Metastases. Adv Radiat Oncol. 2026. PMID: 42540335. doi:10.1016/j.adro.2026.102118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。